On 15 March Orexigen announced the acquisition of US distribution rights to its obesity treatment Contrave from Takeda. The company simultaneously announced a new collaboration with Valeant for the commercialization of Mysimba (Contrave ex-US) in 18 Central and Eastern European countries. We value Orexigen at $213m, significantly reduced from $1.09bn, mainly on reduced expectations for Contrave in the US. However, our fair value of $1.47/share is substantially above the current $0.51 share pr
12 Apr 2016
Taking control of Contrave
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Taking control of Contrave
- Published:
12 Apr 2016 -
Author:
Katherine Genis -
Pages:
8
On 15 March Orexigen announced the acquisition of US distribution rights to its obesity treatment Contrave from Takeda. The company simultaneously announced a new collaboration with Valeant for the commercialization of Mysimba (Contrave ex-US) in 18 Central and Eastern European countries. We value Orexigen at $213m, significantly reduced from $1.09bn, mainly on reduced expectations for Contrave in the US. However, our fair value of $1.47/share is substantially above the current $0.51 share pr